MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 885 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
ARS-1630
CAS:<p>ARS-1630 is a mutant K-ras G12C inhibitor. It is a less active enantiomer of ARS-1620.</p>Formula:C21H17ClF2N4O2Purity:97.78%Color and Shape:SolidMolecular weight:430.84Dilmapimod
CAS:<p>Dilmapimod (SB-681323) is a potent inhibitor of p38 MAPK ,it potentially suppresses inflammation in chronic obstructive pulmonary disease.</p>Formula:C23H19F3N4O3Purity:97.53%Color and Shape:SolidMolecular weight:456.42Cephradine
CAS:<p>Cephradine (Anspor) is a beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity.</p>Formula:C16H19N3O4SPurity:99.63%Color and Shape:White Crystalline Powder; Polymorphic SolidMolecular weight:349.40B-Raf IN 2
CAS:<p>B-Raf IN 2, compound Ia, is a highly effective and specific inhibitor of BRAF. It exhibits significant potential for cancer research.</p>Formula:C20H17F2N5O4SPurity:98.86%Color and Shape:SolidMolecular weight:461.44ERK5-IN-6
CAS:<p>ERK5-IN-6 is an ERK5 kinase inhibitor with antiproliferative, anticonvulsant, and antitumor activity for the study of central nervous system related diseases.</p>Formula:C23H21N3Purity:98.59%Color and Shape:SoildMolecular weight:339.43Xl-281
CAS:<p>XL-281: potent oral RAF kinase inhibitor, effective on wild-type and mutants, reduces tumor growth and cell proliferation, increases apoptosis.</p>Formula:C24H19ClN4O4Purity:95.77% - 98.83%Color and Shape:SolidMolecular weight:462.89CC-90003
CAS:<p>CC-90003 is a selective inhibitor of ERK 1/2. It has antitumor activity.</p>Formula:C22H21F3N6O2Purity:99.42%Color and Shape:SolidMolecular weight:458.44PF-3644022
CAS:<p>PF-3644022 is a selective MK2 inhibitor, effective against TNFα (IC50: 5.2 nM, Ki: 3 nM), with anti-inflammatory properties. Also blocks MK3 and PRAK.</p>Formula:C21H18N4OSPurity:98.13%Color and Shape:SolidMolecular weight:374.46KRAS G12C inhibitor 19
CAS:<p>KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that shows anti-tumor activity in cellular assays, and the family inhibits tumor growth.</p>Formula:C25H19ClF2N4O3SPurity:97.46%Color and Shape:SolidMolecular weight:528.96SU3327
CAS:<p>SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM).</p>Formula:C5H3N5O2S3Purity:98.39%Color and Shape:SolidMolecular weight:261.3MRTX0902
CAS:<p>MRTX0902 is an effective and high selective inhibitor of SOS1 with an IC50 of 46 nM and a Ki of 2 nM.</p>Formula:C22H24N6OPurity:99.69%Color and Shape:SolidMolecular weight:388.47LUT014
CAS:<p>LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.</p>Formula:C27H19F3N8OPurity:99.03%Color and Shape:SolidMolecular weight:528.49HSND80
<p>HSND80 (Compound 1) is an orally active MNK/p70S6K inhibitor, exhibiting a Kd value of 44 nM for MNK1 and 4 nM for MNK2. The residence time of HSND80 on MNK1 and MNK2 is 45 minutes and 58 minutes, respectively. HSND80 effectively inhibits non-small cell lung cancer (NSCLC) both in vitro and in vivo, and suppresses the growth of triple-negative breast cancer (TNBC) cells in vitro.</p>Color and Shape:Odour SolidMitogen-activated protein kinase 1
CAS:<p>Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.</p>Purity:98%Color and Shape:SolidADT-007
CAS:<p>ADT-007 is a pan-RAS inhibitor with potent anticancer activity.</p>Formula:C26H24FNO5Purity:97.75%Color and Shape:SoildMolecular weight:449.47RTIL 13
CAS:<p>RTIL 13 inhibits dynamin GTPase (IC50: 2.3 μM), targets its lipid binding domain, and suppresses endocytosis (IC50: 9.3 & 7.1 μM).</p>Formula:C30H55BrN2O3Color and Shape:SolidMolecular weight:571.685KRAS G12C inhibitor 69
<p>KRAS G12C inhibitor 69 (Compound K09) is an inhibitor of the mutant RAS protein KRAS G12C with an IC50 of 4.36 nM. In the cell lines NCI-H358 and MIA-PACA-2, it suppresses ERK phosphorylation with IC50 values of 12 nM and 7 nM, respectively. Additionally, KRAS G12C inhibitor 69 hinders the proliferation of NCI-H358 and MIA-PACA-2 cancer cells, with IC50 values of 3.15 nM and 2.33 nM, respectively.</p>Formula:C29H29ClF3N5O3Color and Shape:SolidMolecular weight:588.02PROTAC MEK1 Degrader-1
CAS:<p>PROTAC MEK1 Degrader-1, a targeted protein degradation agent, combines a MEK1 inhibitor with a von Hippel-Lindau ligand to effectively inhibit ERK1/2</p>Formula:C53H66FIN8O11S2Purity:98%Color and Shape:SolidMolecular weight:1201.17R18
CAS:<p>14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.</p>Formula:C101H157N27O29S3Purity:98%Color and Shape:SolidMolecular weight:2309.69BI1701963
<p>BI1701963 is an orally effective inhibitor that targets the SOS1 and KRAS interaction, specifically inhibiting the activation of KRAS by blocking its GTP loading. This compound is utilized in cancer research to explore potential therapeutic effects against KRAS-driven malignancies.</p>Formula:C47H62N8O4SColor and Shape:SolidMolecular weight:835.11
